# Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis

> **NCT01433445** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 61 (actual)

## Conditions studied

- Idiopathic Myelofibrosis
- Post Essential Thrombocythemia Myelofibrosis
- Post Polycythemia-Vera Myelofibrosis

## Interventions

- **DRUG:** panobinostat
- **DRUG:** ruxolitinib

## Key facts

- **NCT ID:** NCT01433445
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11-01
- **Primary completion:** 2020-06-22
- **Final completion:** 2020-06-22
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2021-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01433445

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01433445, "Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT01433445. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*